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Abstract
Background: Second neoplasms (SNs) are a well-established long-term adverse effect of radiation
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therapy (RT), but there are limited data regarding their incidence and location relative to the radi-
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ation field, specific to medulloblastoma (MB) survivors after craniospinal irradiation (CSI).
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Methods: A systematic literature review, per Preferred Reporting Items for Systematic Reviews
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and Meta-Analyses, identified six studies reporting the incidence and locations of SNs for 1,114
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patients with MB, after CSI, with a median follow-up of ∼9 years (7.6–15.4 years). The study-
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specific cumulative incidence (CI) of SNs, second benign neoplasms (SBNs), and second malig-
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nant neoplasms (SMNs) were standardized to a 10-year time frame. Meta-analysis was performed
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using random effects models, with pooled data from selected studies and an institutional cohort
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of 55 patients.
Results: The 10-year CI was 6.1% for all SNs (excluding skin cancer and leukemia), 3.1% for SBNs,
and 3.7% for SMNs. Fifty-eight percent of SNs were malignant; high-grade glioma was the most
common SMN (15/33; 45%) and meningioma, the most common SBN (16/24; 67%). Forty percent
of SNs occurred outside the target central nervous system (CNS) field, with a majority in areas of
exit RT dose. Seventy-four percent of extra-CNS tumors (17/23) were malignant, most commonly
thyroid carcinoma (7/17; 41%) and bone and soft-tissue tumors (6/17, 35%).
Conclusions: Survivors of MB are at risk of SNs both within and outside the CNS. A significant
proportion of SNs occur in areas of exit RT dose. Studies are needed to determine whether the use
of proton therapy, which has no exit RT dose, is associated with a lower incidence of SNs.
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1

INTRODUCTION

childhood central nervous system (CNS) tumor survivors more than
10 years off-therapy,8 with the most common SMNs after RT being

Survival has improved significantly for patients with medulloblastoma
(MB), with craniospinal irradiation (CSI) and

chemotherapy,1,2

but at

solid tumors, both within the target radiation field (gliomas and meningiomas) and outside the target field (thyroid cancer and sarcomas).9

the cost of long-term adverse effects including second neoplasms

Reports by the Childhood Cancer Survivor Study (CCSS), British

(SNs).3 SNs are a known long-term adverse effect of radiation therapy

cancer registry, from SEER data, as well as single institutions, describe

(RT),4,5 with the risk increasing with RT dose and follow-up.6,7 Second

the incidence and characteristics of SNs for patients with CNS tumors

malignant neoplasms (SMNs) are the most common cause of death in

as a group. However, the volumes and doses of RT for these patients
differ significantly based on their diagnosis. There are limited data
on the incidence of SNs and their locations relative to the RT

Abbreviations: BCM, Baylor College of Medicine; CNS, central nervous system; CSI,
craniospinal irradiation; MB, medulloblastoma; RT, radiation therapy; SMNs, second
malignant neoplasms; TCH, Texas Children's Hospital
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field, specific to MB, for which the volume irradiated is significantly
greater compared to most other CNS tumors which are treated with
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focal/involved-field RT (e.g. gliomas and ependymoma). Consequently,

(A.C.P.). All titles were initially screened by review of title and abstract,

in patients with MB, a significantly larger volume of healthy tissue

to determine eligibility. Selected publications that appeared to be on

receives an exit RT dose, with the associated risk of SNs.

topic were then assessed in detail to ascertain data availability, com-

We performed a meta-analysis of the incidence and locations of

pleteness, and relevance based on the predetermined inclusion crite-

SNs, relative to the radiation field, for patients treated for MB, with

ria. Papers with missing or duplicated data were further excluded. For

radiation to the craniospinal axis. The analysis included previously

eligible studies, data were extracted as available, including the num-

unpublished data from a single institution and the existing literature

ber of patients with MB treated with CSI, patient characteristics and

identified by a systematic review.

demographics, details of surgery and chemotherapy, dose of CSI, radiation technique, median follow-up, cumulative incidence (CI) of SNs,
second benign neoplasms (SBNs) and SMNs, median interval between

2

METHODS

RT and occurrence of SNs, and the number and characteristics of SNs
in the target field and outside the target field.

2.1

Systematic literature search

A systematic search of the literature was conducted, according to the

2.3

Retrospective study at a single institution

Preferred Reporting Items for Systematic Reviews and Meta-Analyses

Data were included, in this meta-analysis, from a retrospective study

method. A search strategy was developed for Medline (Ovid) using the

of a cohort of 55 consecutive patients with MB, treated at a sin-

following Medical Subject Heading terms: medulloblastoma; nervous

gle institution—Texas Children's Hospital (TCH)/Baylor College of

system neoplasms; brain neoplasms; radiotherapy; radiotherapy, adju-

Medicine (BCM)—between January 1997 and October 2008. Approval

vant; neoplasms, second primary; neoplasms, radiation-induced; child;

was obtained for this study from the institutional review board at

pediatrics; and adolescent. Appropriate synonyms were determined

TCH/BCM.

and searched for as text in article titles, abstracts, and keywords. This
search strategy, listed in full in Supplementary Document S1, was then
translated to the Embase, Scopus, and PubMed databases. After inter-

2.4

Statistical analysis

nal and external deduplication, 2,076 unique titles from the literature

Ten-year CI rates were determined for the following: (a) all SNs (exclud-

search were identified.

ing skin cancer and leukemia), (b) SBNs, (c) SMNs, and (d) skin cancer.
This process involved obtaining the median time to follow-up for all

2.2

Eligibility criteria and data extraction

patients either directly from the manuscript, or by obtaining the overall survival at 3, 5, or 10 years and interpolating to get the median time

In order for studies to be eligible for this meta-analysis, they needed to
report data regarding the incidence and nature of SNs for a cohort of
at least five patients with MB treated with CSI, with a median followup of at least 5 years. The studies could be prospective or retrospective. Two authors (A.B. and S.T.) independently reviewed all 2,076 titles

to follow-up for all subjects from the median time to follow-up for surviving subjects. The study-specific incidence rates were then standardized to a 10-year time frame. Random effects models were used in the
meta-analysis and the combined 10-year CI of SNs was estimated and
tabulated along with 95% confidence intervals.

and identified relevant studies (Figure 1). In case of a disagreement, the
two reviewers were to first attempt to reach a consensus by discussion,
failing which, they were to proceed to arbitration by the senior author

Forest plots illustrating this information were constructed. This was
done for all, benign, malignant, and skin SNs, within and outside the
CNS, that is, the target radiation field. Meta-analyses were performed
using MedCalc for Windows, version 18.0 (MedCalc Software, Ostend,
Belgium). The random effects weighting was implemented using the
Freeman–Tukey transformation.

3
3.1

RESULTS
Systematic literature review

Data from the single-institution (TCH) retrospective review were
pooled with that from six papers identified, by systematic review
of the literature, as meeting inclusion criteria for the meta-analysis
(Table 1).3,10–14 The systematic search of databases yielded 2,076
titles, of which, 1,975 titles were excluded as “not on topic” by review
of the title and/or abstract (Figure 1). Further excluded were 24 conF I G U R E 1 PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) flow diagram

ference abstracts, 14 reviews, seven manuscripts in a language other
than English, and seven abstracts for which full manuscripts could not
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TA B L E 1

Characteristics of included studies

Study

PMID

Era

Craniospinal RT dose
(Gy) median/range

Sample
size

1996–2000

23.4

379

8.9

University of Florida

1963–2008

28.8

53

15.4

CNMC

1969–1997

32–36

82

7.6

NH and NRH

1973–1997

30–36

28

13.5

HIT’91a

1991–1997

35.2

280

8.8

SJCRH

1985–2012

NR

237

10.3

TCH

1997–2008

26

55

8.1

Study population

Packer et al.

COG A9961

a

Median f/u (years)

23099653
Christopherson et al.10
24564687
Stavrou et al.11
11878577
Helseth et al.12
10502004
von Hoff et al.13
19250820
Tsui et al.14
25395462
Bavle et al.

N/A

a

Prospective treatment trial for medulloblastoma.
PMID, Pubmed ID; RT, radiation therapy; f/u, follow-up; COG, Children's Oncology Group; CNMC, Children's National Medical Center, Washington DC;
NH and NRH, The National Hospital and National Radium Hospital in Norway; HIT'91, prospective treatment trial for medulloblastoma; SJCRH, St. Jude
Children's Research Hospital; TCH, Texas Children's Hospital; N/A, not applicable; NR, not reported.

be obtained. The remaining 49 manuscripts were reviewed in detail,

exit radiation, while some bone and soft tissue tumors (5/23; 22%)

with 43 of these papers being excluded despite describing SNs after RT

occurred in the skull, jaw, and nasal cavity, all structures exposed to

due to a lack of data specific to MB/primitive neuroectodermal tumor

entry radiation. The location of SN was not specified for three patients

or CSI in 29 papers; results specific to MB, but with inadequate data for

with osteosarcoma and nerve sheath and desmoid tumors, respectively

meta-analysis in 12

studies7,15–25

(Supplementary Table S1); and less

(Table 3).

than five patients with MB26 and median follow-up less than 1 year27

The 10-year CI of skin malignancies was 1.1 %, with all but one

in one study each. Both reviewers (A.B. and S.T.) agreed that the identi-

patient reported to have basal cell carcinoma (7/8; 88%). Nearly half

fied studies met inclusion criteria.

these patients (3/8; 38%) had a diagnosed germline predisposition syndrome (Gorlin or nevoid basal cell carcinoma syndrome).

3.2

CI of SNs

For 1,114 patients with MB treated with CSI, the overall CI of SNs
(excluding skin cancer), benign and malignant, within and outside the

4

DISCUSSION

CNS (i.e. the target radiation field), are reported in Table 2, Figure 2,
and Supplementary Document S2. Fifty-eight percent (33/57) of SNs

The results of this meta-analysis highlight the increased risk of SNs for

were malignant (Table 3) and high-grade glioma was the most com-

patients with MB compared to other primary CNS tumors; the 10-year

mon SMN (15/33; 45%). Meningioma was the most common SBN

CI of 6.1% for SNs and 3.7% for SMNs is significantly higher for patients

(16/24; 67%). Two patients had low-grade gliomas and one an anaplas-

with MB compared to those reported for all CNS tumors as a group

tic meningioma, with a total of 34 patients developing second tumors

(1.9% and 1.4–1.7%, respectively).16,20 This is likely due to the larger

in the CNS.

volume of radiation (craniospinal) received by patients with MB com-

Forty percent of SNs (23/57) occurred outside the CNS (Table 3).
The most common extra-CNS location for SNs was the thyroid gland

pared to other CNS tumors which are treated with involved-field radiation (e.g. ependymoma and gliomas).

(10/23; 43%). Seventy-four percent of extra-CNS tumors (17/23) were

The 10-year CI in this study is also high compared to results from

malignant, most commonly thyroid carcinoma (7/17; 41%). Nearly two-

larger population-based studies that could not be included for meta-

thirds of extra-CNS SNs (15/23; 65%) were in areas known to receive

analysis (see reasons for exclusion in Supplementary Table S1), with
a reported CI of 3% and 4.4% at 10 years in the SEER16 and St. Jude

TA B L E 2

Ten-year cumulative incidence of second neoplasms

Site of SN

Children's Research Hospital20 databases, respectively, and 7.8% at
30 years in the CCSS cohort.19 This discrepancy could be due to an

SBNs (%)

SMNs (%)

SNs (%)

(95% CI)

(95% CI)

(95% CI)

follow-up, or an overestimation of SNs in our meta-analysis caused by

Within CNS

2.1 (0.9–3.7)

1.9 (1.2–2.8)

3.5 (2.1–5.3)

the inclusion of smaller institutional studies. Consistent with our study,

Outside CNS

0.8 (0.1–2.2)

2.0 (1.1–3.1)

2.7 (1.3–4.5)

analysis of the SEER database found brain tumors to be the most com-

Overall

3.1 (1.4–5.3)

3.7 (2.7–4.9)

6.1 (4.1–8.4)

mon SMN after treatment for MB, followed by thyroid cancer.17

SN, second neoplasm; SBNs, second benign neoplasms; SMNs, second
malignant neoplasms; CNS, central nervous system.

underestimation of SN incidence in the larger studies caused by loss to

We identified six studies in the literature that reported the incidence of SNs for cohorts of patients with MB treated with craniospinal
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F I G U R E 2 Forest plots of pooled analysis with random effects depict the cumulative incidence with 95% confidence interval for (A) second
neoplasms, (B) second benign neoplasms, and (C) second malignant neoplasms

radiation. As individual studies, these reports have limited numbers of

receive exit radiation. A promising strategy to reduce the incidence

patients with MB, and hence provide a less robust picture of the CI and

of SNs is to minimize exit radiation with the use of protons, particles

patterns of location of SNs relative to the radiation field in this spe-

that emit most of their energy within a few millimeters of a partic-

cific patient population. A meta-analysis with pooled data from these

ular depth (Bragg peak) which can be aligned with the target tumor

studies helps address this challenge, estimating the CI for a total of

depth.28 Brodin et al. reported fewer life years lost for patients with

1,114 patients with a median follow-up of ∼9 years (7.6–15.4 years).

MB treated with intensity-modulated proton therapy compared to two

The results highlight the significant toxicities of radiation—a crucial

photon radiation techniques (3D conformal radiotherapy and volu-

treatment modality for disease cure. While more than a third of these

metric modulated arc therapy), based on excess hazard ratios for sec-

tumors were benign, and hence likely curable, their treatment would

ond cancers and cardiac complications in the exit dose region.29 How-

often involve surgery (e.g. meningioma and thyroid papilloma) and the

ever, this study did not take into account SMNs within the CNS, which

resulting morbidity. More than half of the reported SNs were malig-

constituted nearly half of the cases in our analysis. This significant

nant, with many of these tumors considered incurable (e.g. glioblas-

adverse event must be considered in future modeling studies estimat-

toma multiforme) or with poor survival (e.g. osteosarcoma).

ing the risk of late effects of CSI. One retrospective study largely with

More than a third of SNs occurred outside the intended target radi-

adult patients30 and another using a prediction model31 also suggest a

ation field. While some occurred in areas that would receive entry radi-

reduced risk of SMNs with protons compared to conventional photon

ation, at least 65% percent of these cases involved areas predicted to

RT. Prospective studies with proton RT in a pediatric MB cohort, with
sufficiently long follow-up, are needed to determine the effectiveness

TA B L E 3

Characteristics of second neoplasms

of this strategy.
Only two of six studies in this meta-analysis were prospective with

Second neoplasm
location (total)

Second benign
neoplasms

Second malignant
neoplasms

Overall (57)

24 (42%)

33 (58%)

Within CNS (34)

18 (53%)

16 (47%)

Outside CNS (23)

6 (26%)

17 (74%)

- Thyroid
adenoma (3)

- Thyroid carcinoma (7)

- Osteoma of jaw
(1)

- Soft-tissue tumors
(3)d

- Desmoid tumora
(1)
- Cardiac tumor
(1)b

- Osteosarcomac (3)

- Testicular mixed
malignant germ cell
tumor (1)
- Ovarian
adenocarcinoma (1)
- Salivary gland
carcinoma (1)e
- Intestinal
adenocarcinoma (1)

all patients receiving uniform treatment.3,13 The remaining four studies and the outcomes of the TCH cohort were retrospective reports
from single institutions. Study populations were treated in different
treatment eras, ranging from 1963 to 2012. The type and intensity of
chemotherapy and the dose and modality of radiation delivery have
evolved significantly over this time period. The exit dose of radiation is
likely to have been greater with older modalities of conventional radiation, while being better limited with more modern techniques such as
intensity-modulated RT (IMRT). Indeed, of seven studies, five reported
outcomes for patients treated prior to the late 1990s, when IMRT
began to be more widely used. The risk of SNs has been unequivocally
demonstrated previously to correlate with radiation dose. The dose of
radiation in this meta-analysis varied (23.4–36 Gy), with the median
RT dose being less than 30 Gy in three studies, greater than 30 Gy in
three studies, and not being reported in one study. The available data

a

were inadequate to analyze the impact of this factor on the incidence

b

of SNs. Due to the unavailability of data regarding the actual radia-

Desmoid tumor location not specified.
Not biopsied and counted as benign tumor for analysis.
c
Osteosarcoma of skull and temporal bone, with location not specified for
one patient.
d
Soft-tissue tumors included nasal cavity rhabdomyosarcoma, nasal spindle
cell carcinoma, and nerve sheath tumor, location not specified.
e
Mammary analog secretory carcinoma.
CNS, central nervous system.

tion fields received by patients, solid tumors occurring outside the CNS
were presumed to occur due to entry or exit radiation in our analysis.
Other factors, such as chemotherapy and undiagnosed germline cancer
predisposition syndromes, could have contributed to the occurrence
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of some of these SNs, and could not be evaluated in our study. The
follow-up in studies was not long enough to determine the incidence
and nature of SNs in subsequent decades beyond 10 years, an important consideration in long-term survivors of pediatric tumors. Studies
of late effects of treatment for pediatric CNS tumors have shown a continued increased incidence of SNs such as meningiomas and thyroid
cancer with longer follow-up.17,19 The morbidity and mortality of SNs
for patients could also not be determined in this analysis.
This meta-analysis strengthens the conclusion of smaller studies,
that patients with MB treated with CSI are at risk for a variety of SNs
with a wide anatomic distribution, reflective of the large radiation volume. A significant proportion of these SNs occur outside the target
radiation field, highlighting the importance of minimizing exit radiation.
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